Karuppagounder, Senthilkumar S.

Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease

Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 1,397

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease

Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine

Neuroinflammation and Neurodegeneration MechanismsParkinson's Disease Mechanisms and Treatments

Cited by 1,123

Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease

Kam, T.-I., Mao, X., Park, H., Chou, S.-C., Karuppagounder, S. S., Umanah, G. E., Yun, S. P., Brahmachari, S., Panicker, N., Chen, R., et al. (2018) · Science

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 476

Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis

Andrabi, S. A., Umanah, G. K. E., Chang, C., Stevens, D. A., Karuppagounder, S. S., Gagné, J.-P., Poirier, G. G., Dawson, V. L., & Dawson, T. M. (2014) · Proceedings of the National Academy of Sciences

PARP inhibition in cancer therapyCell death mechanisms and regulation

Cited by 307

The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease

Karuppagounder, S. S., Brahmachari, S., Lee, Y., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2014) · Scientific Reports

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 264

STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy

Hinkle, J. T., Patel, J., Panicker, N., Karuppagounder, S. S., Biswas, D., Belingon, B., Chen, R., Brahmachari, S., Pletnikova, O., Troncoso, J. C., et al. (2022) · Proceedings of the National Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 240

Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss

Lee, Y., Karuppagounder, S. S., Shin, J.-H., Lee, Y.-I., Ko, H. S., Swing, D., Jiang, H., Kang, S.-U., Lee, B. D., Kang, H. C., et al. (2013) · Nature Neuroscience

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 214

Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin

Kam, T.-I., Park, H., Chou, S.-C., Van Vranken, J. G., Mittenbühler, M. J., Kim, H., A, M., Choi, Y. R., Biswas, D., Wang, J., et al. (2022) · Proceedings of the National Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 125

The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results

Lyden, P. D., Bosetti, F., Diniz, M. A., Rogatko, A., Koenig, J. I., Lamb, J., Nagarkatti, K. A., Cabeen, R. P., Hess, D. C., Kamat, P. K., et al. (2022) · Stroke

Acute Ischemic Stroke ManagementAnimal testing and alternatives

Cited by 73

Enhanced mTORC1 signaling and protein synthesis in pathologic α-synuclein cellular and animal models of Parkinson’s disease

Khan, M. R., Yin, X., Kang, S.-U., Mitra, J., Wang, H., Ryu, T., Brahmachari, S., Karuppagounder, S. S., Kimura, Y., Jhaldiyal, A., et al. (2023) · Science Translational Medicine

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 64

Enhanced mTORC1 signaling and Protein Synthesis in Parkinson’s Disease Pathogenesis Disease Pathogenesis

Khan, M. R., Yin, X., Kang, S.-U., Mitra, J., Wang, H., Brahmachari, S., Karuppagounder, S. S., Kimura, Y., Jhaldiyal, A., Kim, H. H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory)

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 0